Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Saskatchewan

$27,000.00

Preclinical studies of a novel oligonucleotide therapeutic (OT) delivery platform in a humanized mouse model of HIV infection

EF 2024-25

Résumé
HIV currently infects about 39 million people world-wide and there is no cure. Current anti-retroviral therapy (ART) targets multiple steps in the HIV life cycle to reduce or eliminate the live viruses in HIV patients blood. However, HIV inserts its genetic material into the host DNA and, despite ART, continues to try and replicate to produce more live viruses. This continued abortive HIV replication remains a longstanding unresolved issue in the treatment of people living with HIV as it is thought to contribute to the persistent inflammation that drives HIV-related illnesses and immune dysfunction in ART-treated patients. In collaboration with an industry partner, we will assess a novel therapeutic that can potentially target and reduce or eliminate the residual abortive HIV replication. By reducing residual abortive replication, the therapeutics we will test have the potential to be a much-needed novel class of antiviral agents that can reduce the inflammation and immune dysfunction in HIV patients that persist despite effective ART. Similar drugs are in clinical trials for other diseases but often fail to become therapeutics due to their high toxicity or inability to penetrate important tissues in the body. Our industry partner has produced a novel technology that makes these therapeutics much more effective at entering cells and tissues, thereby requiring much lower doses and thus resulting in lower toxicity. Our research will aim to test and optimize the use of these therapeutics in an animal model of HIV infection. Specifically, we aim to evaluate if these therapeutics can effectively penetrate all relevant tissues and if they can reduce or eliminate the residual abortive HIV replication that occurs despite effective ART treatment.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530034
Name
Chang Vianne
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preclinical studies of a novel oligonucleotide therapeutic (OT) delivery platform in a humanized mouse model of HIV infection
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Model; Antiviral Drugs; Antretroiviral Therapy; Drug Delivery; Hiv Reservoirs; Hiv/Aids; Humanized Mice; Immunodeficiency; Oligonucleotide Therapeutics; Viral Replication
Abstract
HIV currently infects about 39 million people world-wide and there is no cure. Current anti-retroviral therapy (ART) targets multiple steps in the HIV life cycle to reduce or eliminate the live viruses in HIV patients blood. However, HIV inserts its genetic material into the host DNA and, despite ART, continues to try and replicate to produce more live viruses. This continued abortive HIV replication remains a longstanding unresolved issue in the treatment of people living with HIV as it is thought to contribute to the persistent inflammation that drives HIV-related illnesses and immune dysfunction in ART-treated patients. In collaboration with an industry partner, we will assess a novel therapeutic that can potentially target and reduce or eliminate the residual abortive HIV replication. By reducing residual abortive replication, the therapeutics we will test have the potential to be a much-needed novel class of antiviral agents that can reduce the inflammation and immune dysfunction in HIV patients that persist despite effective ART. Similar drugs are in clinical trials for other diseases but often fail to become therapeutics due to their high toxicity or inability to penetrate important tissues in the body. Our industry partner has produced a novel technology that makes these therapeutics much more effective at entering cells and tissues, thereby requiring much lower doses and thus resulting in lower toxicity. Our research will aim to test and optimize the use of these therapeutics in an animal model of HIV infection. Specifically, we aim to evaluate if these therapeutics can effectively penetrate all relevant tissues and if they can reduce or eliminate the residual abortive HIV replication that occurs despite effective ART treatment.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chang, Vianne
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~